Understanding Immune Responses to COVID-19
This observational study aims to understand how your body's immune system (its defense against germs) responds to COVID-19, both during the infection and as you recover. Researchers will look at how these immune responses might lead to different outcomes, from mild symptoms to more severe illness. They will also search for genetic differences that might make some people more resistant to the virus or more likely to have a severe case. This study is collecting samples from people of all ages, from newborns to 99 years old, who have or are suspected of having COVID-19 or other respiratory viruses. The goal is to learn more about how our bodies fight off these infections.
- Study design
- This is an observational study planning to enroll up to 5000 participants. It involves collecting samples over time to understand immune responses.
- What's involved
- You would provide biological samples like blood, saliva, stool, or urine. You will not have study visits at the NIH.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goals of the study are measured at the end of the study, but a specific follow-up duration is not provided.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Helen C Su, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence.End of Study
These endpoints were chosen to provide in depth molecularmeasurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
- Identification of genetic variants that are associated with either severe/lethal COVID-19 or resistance to SARS CoV 2 infection.End of Study
These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immune responses to a novel pathogen in heterogenous patients. This is an exploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
- Measurement of proinflammatory/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response.End of Study
These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immune responses to a novel pathogen in heterogenous patients. This is an exploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
- Survey of other potential blood proteomic biomarkers of disease.End of Study
These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immune responses to a novel pathogen in heterogenous patients. This is an exploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
- Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens.End of Study
These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immune responses to a novel pathogen in heterogenous patients. This is an exploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
- Characterization of intrapatient SARS-CoV-2 genetic variation and evolution during infection and convalescence.End of Study
These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immune responses to a novel pathogen in heterogenous patients. This is an exploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.